SearchDictionaryMobileLogin

Effect of nonergot dopamine agonists on symptoms of restless legs syndrome.

AbstractPURPOSE: We performed a meta-analysis of randomized placebo-controlled trials of nonergot dopamine agonists (NEDAs) for the treatment of restless legs syndrome. METHODS: A systematic literature search was conducted through July 2007. The primary outcome measures assessed were the percentage of responders to medication as determined by the Clinical Global Impression-Improvement (CGI-I) scale and the adjusted mean change in the International Restless Legs Syndrome Study Group Scale (IRLS) score from baseline compared with placebo. Meta-regression analysis was performed to evaluate the impact of study duration on the primary outcomes. Safety endpoints were also evaluated. RESULTS: A total of 14 trials (n = 3,197 subjects) were included in the meta-analysis. NEDA use resulted in greater response as measured by the CGI-I scale (relative risk [RR] 1.36; 95% CI, 1.24 to 1.49; P <.001), and greater reductions in IRLS scores (weighted mean difference [WMD] -4.93; 95% CI, -6.42 to -3.43; P <.001) from baseline vs placebo. Meta-regression analysis showed an inverse relationship between study duration and reduction in IRLS score. NEDAs were associated with a significant risk of adverse events (including nausea, dizziness, somnolence, and fatigue.) CONCLUSIONS: Use of NEDAs in patients with moderate-to-severe restless legs syndrome results in significant reductions in symptom severity, but a significant portion of patients will discontinue their use as a result of adverse events.
AuthorsWilliam L Baker, C Michael White, Craig I Coleman (Affiliation: University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.)
JournalAnnals of family medicine (Ann Fam Med) 2008 May-Jun Vol. 6 Issue 3 Pg. 253-62 ISSN: 1544-1717 United States
PMID18474889 (Publication Type: Journal Article, Meta-Analysis, Review)
Chemical References
  • Dopamine Agonists
  • Ergot Alkaloids
Topics
  • Dopamine Agonists (therapeutic use)
  • Dose-Response Relationship, Drug
  • Ergot Alkaloids (therapeutic use)
  • Humans
  • Randomized Controlled Trials as Topic
  • Regression Analysis
  • Restless Legs Syndrome (drug therapy)
  • Treatment Outcome